Neuranics Raises $700K In Seed Funding To Revolutionise Blood Diagnostics

Healthcare diagnostics startup Neuranics has raised USD 7,00,000 in a seed funding round led by Inflection Point Ventures (IPV). The funding will be used to advance technology development, and clinical validation, and prepare the company for commercial production post-CDSCO licensing.

Neuranics has developed an innovative point-of-care blood analyser capable of delivering complete blood count (CBC) results within 10 minutes using just a finger-prick sample. This groundbreaking device eliminates the need for liquid reagents and extensive maintenance, making it highly suitable for primary and emergency healthcare settings.

The compact dry haematology analyser addresses critical challenges in diagnostics by offering immediate, actionable results. Praveen Kumar, Co-founder and CEO of Neuranics stated, “We are re-imagining how diagnostics are conducted, bringing instant and accurate blood analysis closer to the patient without compromising quality. This technology empowers clinicians with real-time data, transforming care delivery and improving patient outcomes.”

Dr. Megha Sharma, Chief Medical Evangelist at Neuranics, emphasised the impact on patient care: “Our CBC analyser eliminates the need for traditional venipuncture, providing faster, less invasive, and more patient-friendly diagnostics. It is particularly impactful for primary healthcare centres and emergency triage setups.”

The device facilitates swift diagnosis and treatment for conditions like sepsis, severe anaemia, and dengue-related thrombocytopenia, improving outcomes while reducing healthcare costs.

Founded in 2021 by Praveen Kumar and Ashutosh Patra, Neuranics has made significant strides in the diagnostics sector, achieving milestones such as a granted patent, CDSCO Test License, and Ethical Approval from AIIMS Delhi. The startup has progressed through clinical trials and garnered recognition from initiatives like YourStory Tech30, Amazon-Sambhav, and the India-Sweden Innovation Challenge.

Ashutosh Patra, Co-founder and CTO, noted the importance of innovation: “Leveraging our expertise in robotics, machine vision, and microfluidics, we aim to set new benchmarks in diagnostic technology, decentralising routine diagnostics for quicker, more accessible solutions.”

Mitesh Shah, Co-founder of IPV, expressed confidence in Neuranics: “Their point-of-care blood analyser addresses critical challenges in healthcare by making CBC diagnosis faster and easier. We believe in their innovative technology and its potential to transform patient care.”

The global CBC market, valued at USD 50 billion, is expanding at a CAGR of 8-10 per cent, presenting significant opportunities for Neuranics.